Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Completed · Phase 3 · NCT04164199
Conditions: Advanced Malignancies
At a glance
- Research payments reported, 2025
- $4,458
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 404
About the trial
- Sponsor
- BeOne Medicines
- Tested
- Tislelizumab (drug), Pamiparib (drug), Temozolomide (drug), Sitravatinib (drug), Ociperlimab (drug), BAT1706 (drug), Fruquintinib (drug), BGB-15025 (drug), Zanidatamab (drug), BGB-A445 (drug), Surzebiclimab (drug), Lenvatinib (drug), LBL-007 (drug)
- Dates
- Started 2019-12-19; completion 2026-05-23
- Results posted
- Not yet
This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene or BeOne investigational drugs in participants with advanced malignancies who participated in a prior BeiGene- or BeOne-sponsored clinical study (parent study).
From ClinicalTrials.gov, last updated 2026-06-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $4,458 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.